NCT04063020 (EPCHIRPRORL) is a clinical trial of Psychological monitoring in Ear Aplasia, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT04063020?

NCT04063020 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT04063020?

Interventions in NCT04063020: Psychological monitoring.

What condition does NCT04063020 study?

NCT04063020 studies Ear Aplasia.

Is NCT04063020 still recruiting?

NCT04063020 is currently completed. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT04063020: EPCHIRPRORL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychic Stakes of Reconstructive Plastic Surgery in Children With Ear Aplasia

Completed Last updated 31 March 2026

What this trial tests

trial testing Psychological monitoring in Ear Aplasia in 12 participants. Completed in 23 December 2022.

Timeline

18 January 2020

Primary endpoint
23 December 2022

23 December 2022

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12
Start date	18 January 2020
Primary completion	23 December 2022
Estimated completion	23 December 2022
Sites	1 location across France

Drugs / interventions tested

Psychological monitoring

Conditions studied

Ear Aplasia — all drugs for Ear Aplasia →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 10 to 16, any sex, with Ear Aplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to analyse : * Psychic experience of ear aplasia in children ; * the modalities of their psychic functioning ; * and the psychological repercussions of the plastic reconstruction surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04063020 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04063020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing